Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q1 2022 · 10-Q
Revenue$11.90B$11.90B+13.8% vs Q1 2021 Net Income$2.45B$2.45B+36.5% vs Q1 2021 EPS Diluted$1.37$1.37+37.0% vs Q1 2021 Operating Income$2,912,000,000+38.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Free Cash Flowderived$1,744,000,000−22.1% Margins · derivedOperating margin24.5%+4.3 pt vs Q1 2021
Net margin20.6%+3.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 3, 2022 · 33 d after period end